18F-FDG PET/CT Compared to Conventional Imaging Modalities in Pediatric Primary Bone Tumors

Overview

Journal Pediatr Radiol

Specialty Pediatrics

Date 2011 Dec 3

PMID 22134535

Citations 20

Authors

Kevin London

Claudia Stege

Siobhan Cross

Ella Onikul

Nicole Graf

Gertjan Kaspers

Luciano Dalla-Pozza

Robert Howman-Giles

Affiliations

Soon will be listed here.

Abstract

Background: F-Fluoro-2-deoxy-D: -glucose (FDG) positron emission tomography (PET) is useful in adults with primary bone tumors. Limited published data exist in children.

Objective: To compare hybrid FDG positron emission tomography/computed tomography (PET/CT) with conventional imaging (CI) modalities in detecting malignant lesions, predicting response to chemotherapy and diagnosing physeal involvement in pediatric primary bone tumors.

Materials And Methods: Retrospective analysis of PET/CT and CI reports with histopathology or follow-up > 6 months as reference standard. Response parameters and physeal involvement at diagnosis were compared to histopathology.

Results: A total of 314 lesions were detected in 86 scans. Excluding lung lesions, PET/CT had higher sensitivity and specificity than CI (83%, 98% and 78%, 97%, respectively). In lung lesions, PET/CT had higher specificity than CI (96% compared to 87%) but lower sensitivity (80% compared to 93%). Higher initial SUV(max) and greater SUV(max) reduction on PET/CT after chemotherapy predicted a good response. Change in tumor size on MRI did not predict response. Both PET/CT and MRI were very sensitive but of low specificity in predicting physeal tumor involvement.

Conclusion: PET/CT appears more accurate than CI in detecting malignant lesions in childhood primary bone tumors, excluding lung lesions. It seems better than MRI at predicting tumor response to chemotherapy.

Citing Articles

A third of the radiotracer dose: two decades of progress in pediatric [F]fluorodeoxyglucose PET/CT and PET/MR imaging.

Waelti S, Skawran S, Sartoretti T, Schwyzer M, Gennari A, Mader C Eur Radiol. 2023; 34(5):3252-3259.

PMID: 37855853 PMC: 11126459. DOI: 10.1007/s00330-023-10319-6.

Update in Imaging Evaluation of Bone and Soft Tissue Sarcomas.

Guedes A, Dos Reis Oliveira M, Melo A, Canella Moraes Do Carmo C Rev Bras Ortop (Sao Paulo). 2023; 58(2):179-190.

PMID: 37252301 PMC: 10212631. DOI: 10.1055/s-0041-1736569.

Imaging of pediatric bone tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper.

Cederberg K, Iyer R, Chaturvedi A, McCarville M, McDaniel J, Sandberg J Pediatr Blood Cancer. 2022; 70 Suppl 4:e30000.

PMID: 36250990 PMC: 10661611. DOI: 10.1002/pbc.30000.

Current progress and future trends in imaging of musculoskeletal bone tumours.

Rajakulasingam R, Botchu R J Clin Orthop Trauma. 2021; 23:101622.

PMID: 34707971 PMC: 8522479. DOI: 10.1016/j.jcot.2021.101622.

Is It Time to Call Time on Bone Marrow Biopsy for Staging Ewing Sarcoma (ES)?.

Ingley K, Wan S, Voo S, Windsor R, Michelagnoli M, Saifuddin A Cancers (Basel). 2021; 13(13).

PMID: 34209887 PMC: 8267963. DOI: 10.3390/cancers13133261.

References

Schulte M, Werner M, Hartwig E, Sarkar M, Keppler P, Kotzerke J . Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999; 40(10):1637-43. View

Franzius C, Daldrup-Link H, Wagner-Bohn A, Sciuk J, Heindel W, Jurgens H . FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol. 2002; 13(1):157-60. DOI: 10.1093/annonc/mdf012. View

Christensen J, Nathan M, Mullan B, Hartman T, Swensen S, Lowe V . Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. AJR Am J Roentgenol. 2006; 187(5):1361-7. DOI: 10.2214/AJR.05.1166. View

Furth C, Steffen I, Amthauer H, Ruf J, Misch D, Schonberger S . Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. J Clin Oncol. 2009; 27(26):4385-91. DOI: 10.1200/JCO.2008.19.7814. View

Bielack S, Kempf-Bielack B, Delling G, Exner G, Flege S, Helmke K . Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002; 20(3):776-90. DOI: 10.1200/JCO.2002.20.3.776. View

Bredella M, Caputo G, Steinbach L . Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol. 2002; 179(5):1145-50. DOI: 10.2214/ajr.179.5.1791145. View

Hawkins D, Conrad 3rd E, Butrynski J, Schuetze S, Eary J . [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults. Cancer. 2009; 115(15):3519-25. PMC: 2716419. DOI: 10.1002/cncr.24421. View

Hawkins D, Schuetze S, Butrynski J, Rajendran J, Vernon C, Conrad 3rd E . [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol. 2005; 23(34):8828-34. DOI: 10.1200/JCO.2005.01.7079. View

Saifuddin A . The accuracy of imaging in the local staging of appendicular osteosarcoma. Skeletal Radiol. 2002; 31(4):191-201. DOI: 10.1007/s00256-001-0471-y. View

10.

Schuetze S, Rubin B, Vernon C, Hawkins D, Bruckner J, Conrad 3rd E . Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2004; 103(2):339-48. DOI: 10.1002/cncr.20769. View

11.

Franzius C, Sciuk J, Brinkschmidt C, Jurgens H, Schober O . Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000; 25(11):874-81. DOI: 10.1097/00003072-200011000-00004. View

12.

Volker T, Denecke T, Steffen I, Misch D, Schonberger S, Plotkin M . Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol. 2007; 25(34):5435-41. DOI: 10.1200/JCO.2007.12.2473. View

13.

Benz M, Evilevitch V, Allen-Auerbach M, Eilber F, Phelps M, Czernin J . Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors. J Nucl Med. 2008; 49(7):1038-46. PMC: 4070847. DOI: 10.2967/jnumed.107.050187. View

14.

Eary J, OSullivan F, Powitan Y, Chandhury K, Vernon C, Bruckner J . Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002; 29(9):1149-54. DOI: 10.1007/s00259-002-0859-5. View

15.

Panuel M, Gentet J, Scheiner C, Jouve J, Bollini G, Petit P . Physeal and epiphyseal extent of primary malignant bone tumors in childhood. Correlation of preoperative MRI and the pathologic examination. Pediatr Radiol. 1993; 23(6):421-4. DOI: 10.1007/BF02012438. View

16.

Franzius C, Bielack S, Flege S, Sciuk J, Jurgens H, Schober O . Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med. 2002; 43(8):1012-7. View

17.

Davis A, Bell R, Goodwin P . Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 1994; 12(2):423-31. DOI: 10.1200/JCO.1994.12.2.423. View

18.

Costelloe C, Macapinlac H, Madewell J, Fitzgerald N, Mawlawi O, Rohren E . 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med. 2009; 50(3):340-7. DOI: 10.2967/jnumed.108.058461. View

19.

Cheon G, Kim M, Lee J, Lee S, Cho W, Song W . Prediction model of chemotherapy response in osteosarcoma by 18F-FDG PET and MRI. J Nucl Med. 2009; 50(9):1435-40. DOI: 10.2967/jnumed.109.063602. View

20.

Bossuyt P, Reitsma J, Bruns D, Gatsonis C, Glasziou P, Irwig L . Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin Radiol. 2003; 58(8):575-80. DOI: 10.1016/s0009-9260(03)00258-7. View